skip to contents
Dr. Amit Bar-Or was recently recruited to the University of Pennsylvania where he holds the Melissa and Paul Anderson Professorship of Neurology and Presidential Endowed Chair, and serve as founder and Director of the Centre for Neuroinflammation and Experimental Therapeutics as well as Chief of the Division of Multiple Sclerosis. He was previously Professor in the Department of Neurology and Neurosurgery, and Associate Director of the Montreal Neurological Institute and Hospital, McGill University. His clinical focus continues to be Multiple Sclerosis (MS) and related disorders in both adults and children. He runs a cellular and molecular Neuroimmunology lab at Penn and CHOP with major research themes directed at understanding basic principles of immune regulation and immune-neural interaction, and their contribution to inflammation, injury and repair of the human central nervous system (CNS). Particular areas of focus have involved elucidation of antibody-independent mechanisms by which human B cells contribute to modulation of T cell and myeloid cell subsets and how these contribute to MS immune pathophysiology; studies of immune reconstitution biology; and mechanisms of neuro-immune interaction. A major translational paradigm that has yielded key discoveries in human autoimmune disease has been our integration of rigorously developed immune monitoring and imaging strategies to well-characterized patient cohorts prospectively followed in biological proof-of-principle therapeutic trials. These studies not only contribute to elucidating a therapy's mode-of action, but also provide a unique window into human disease mechanisms, and development of clinically meaningful biomarkers as part of advancing precision medicine in autoimmune diseases. Reflecting this expertise, he continues to serve as an active member of the Steering Committee of the NIH Immune Tolerance Network (ITN).
He is passionate about education and mentoring, having trained in his lab over 80 students at all levels, with emphasis on clinician-scientist trainees, all of whom have continued active and successful careers at the clinical-research interface. he has published over 230 peer-reviewed publications, led multiple national and international collaborative research initiatives and is considered a highly sought after speaker. he served as past President of the Canadian Network of MS Clinics (CNMSC) and past member of the Board of Directors of the Federation of Clinical Immunology Societies (FOCIS), where he continues to serve on the Education Committee. He is a member of the Board of Directors of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and currently serve as President, and long-standing Scientific Advisory Board member, of the International Society of Neuroimmunology (ISNI).